tbuckley/cabot-search huggingface dataset:
Annals Story Slam - Getting Home
Authors: Janelle Mirabeau
Journal: Annals of Internal Medicine (2017)

Web Exclusives19 December 2017Annals Story Slam - Getting HomeFREEJanelle Mirabeau, CCRNJanelle Mirabeau, CCRNUniversity of Pennsylvania, Philadelphia, Pennsylvania (J.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0073 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Getting Home "Getting Home," by Janelle Mirabeau (Duration 5:01)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: University of Pennsylvania, Philadelphia, Pennsylvania (J.M.)Current Author Address: Janelle Mirabeau, CCRN; e-mail, janelle.[email protected]upenn.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 December 2017Volume 167, Issue 12Page: SS1 ePublished: 19 December 2017 Issue Published: 19 December 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Update on the 2nd Bioactive Materials Editorial Board Meeting
Authors: Mark P. Staiger
Journal: Bioactive Materials (2017)

Board Meeting was held on the 28th August 2017 during the 9th Symposium on Biodegradable Metals for Biomedical Applications (http://biodegradablemetals.org).(see Figs. 1 and2)The Symposium was held in Bertinoro Italy ( Emilie-Romagne region), 80 km southeast of Bologna.Every year the Symposium attracts ~150 participants working in the field of biodegradable metallic biomaterials, mainly based on Mg, Fe and Zn, with ~50 oral presentations and 90 posters delivered at the 9th Symposium by participants from 22 countries.Sessions were organised into a range of topics including metallurgy (alloying and processing, coatings, material properties, and corrosion), research concerned with testing in vitro and in vivo, and other important aspects of biological characterisation.This year the Symposium also hosted a workshop on the "Current Status and Outlook on the Clinical Translation of Biodegradable Metals" organised by Prof. Yufeng Zheng and A/Prof.Mark Staiger.The workshop included keynote presentations and a panel discussion delivered by prominent leaders in the field.Some key areas of discussion included standardization of testing of biometal devices, current translational research in Australasia, Japan, China and South Korea, and various topics concerned with commercialisation of biodegradable metals.The Symposium was an ideal opportunity for the editorial team of Bioactive Materials to promote the journal and review its progress over the last 12 months.
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
Authors: Emily B. Ehlerding, Xiaoli Lan, Weibo Cai
Journal: Theranostics (2017)

Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for "albumin hitchhiking" resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy. Upon clinical translation, such "albumin hitchhiking" could make significant impact in the near future for cancer patient management.
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
Authors: Cesar Serrano-Garcia, Michael C. Heinrich, Meijun Zhu, Chandrajit P. Raut, Grant Eilers, Gloria Ravegnini, George D. Demetri, Sebastian Bauer, Jonathan A. Fletcher, Suzanne George
Journal: Journal of Clinical Oncology (2013)

10510 Background: KIT and PDGFRA mutations (mut) are the crucial transforming events in most GISTs, and tyrosine kinase inhibitors (TKIs) with activity against KIT and PDGFRA, such as imatinib (IM) (front-line therapy) and sunitinib (SU) (second-line therapy), are effective treatments in GIST patients (pts). Resistance to IM and SU is commonly associated with evolution of secondary kinase mut. REGO is a multi-targeted TKI that inhibits KIT, PDGFR, and other oncologic targets and has recently shown benefit in pts with metastatic GIST after progression on standard treatments. We evaluated the in vitro and in vivo activity of REGO compared with IM, SU, and sorafenib (SOR) (a multi-TKI structurally related to REGO). Methods: REGO, IM, SU, and SOR inhibition of viability and KIT phosphorylation was assessed in human GIST cell lines and in Ba/F3 cells transformed by KIT oncoproteins with IM-resistant ATP binding pocket or activation-loop mut. KIT/PDGFRA genotyping was performed in GISTs responding or progressing on REGO in the academic phase II clinical trial. Results: In GISTs with KIT exon 11 mutant oncoproteins, REGO potently inhibited viability, KIT phosphorylation, and downstream effector phosphorylation (AKT, MAPK, S6). IM-resistant activation loop mut were more potently inhibited by REGO than SU, whereas the gatekeeper IM-resistant mut T670I was inhibited by both REGO and SU, and the common ATP-binding pocket mutant V654A was more potently inhibited by SU than REGO. Two GIST metastases progressing in one pt after initial response to REGO contained KIT V654A mut. SOR and REGO demonstrated comparable in vitro overall activity. Representative GIST cell line viability IC50s are shown in the Table (values in bold indicate expected clinical relevance). Conclusions: In vitro studies confirm REGO is a potent inhibitor of KIT exon 11 mut in GIST and appears to have stronger activity than SU against the most common KIT activation-loop mut observed in GIST. Ongoing clinical correlative analyses from REGO-treated study patients will be presented. [Table: see text]
Outbreak of Clostridium difficile 027 in North Zealand, Denmark, 2008-2009
Authors: S Bacci, G St-Martin, B Olesen, B Bruun, K EP Olsen, E Møller Nielsen, K Mølbak
Journal: Eurosurveillance (2009)

We report an outbreak of Clostridium difficile PCR ribotype 027 in Denmark. The outbreak includes to date 73 cases from the area north of Copenhagen, but there may be related cases elsewhere in Zealand. Most infections are healthcare-associated and in patients who previously received antibiotic treatment. The strain is resistant to moxifloxacin, erythromycin, and clindamycin, and carries genes for toxin A, toxin B, and for the binary toxin. The antimicrobial pattern differs from that of the strain involved in a small cluster in Denmark in 2006-2007. Because of this outbreak, hygienic measures in the involved hospitals have been reinforced. Nationwide, microbiological laboratories were alerted to the outbreak and encouraged to send isolates for toxin profiling and PCR ribotyping.
Simultaneous inhibition of α4/β7 integrin and tumour necrosis factor-α in concomitant spondyloarthritis and inflammatory bowel disease
Authors: Nicolas Richard, Elizabeth M Hazel, Nigil Haroon, Robert D Inman
Journal: Annals of the Rheumatic Diseases (2017)

We read with interest the article by Varkas et al 1 suggesting a temporal association between the initiation of vedolizumab (VDZ) for inflammatory bowel disease (IBD) and induction or worsening of spondyloarthritis (SpA). This suggests that in patients with IBD, there may be limited efficacy of α4/β7 integrin blockade for management of extraintestinal manifestations, particularly for arthritis and sacroiliitis.2 3 Treatment of SpA in subjects on VDZ for associated IBD is highly challenging for the treating physician. We describe below two patients who were treated with a combination treatment of VDZ and certolizumab pegol …
Immunoprofiling in alveolar soft part sarcoma.
Authors: Samer Salah, Jeremy Howard Lewin, Scott Davidson, Nathaniel Anderson, Sergio L Periera, Beatrice Lau, Adam Shlien, Brendan Dickson, Peter Ferguson, Jay Wunder, Albiruni Ryan Abdul Razak
Journal: Journal of Clinical Oncology (2017)

11059 Background: Alveolar Soft Part Sarcoma (ASPS) is a distinctive tumor characterized by a canonical ASPL-TFE3 fusion. Treatment options are limited. We assessed tumor immune cell infiltrates, and correlated this with patients receiving PD-1 blockade. Methods: A retrospective institutional review was performed for 18 cases of ASPS. Immunohistochemistry was performed on paraffin-embedded tissue (PET) for T-lymphocyte markers (CD3/CD4/CD8), and PD-1/PD-L1 (Ventana). Expression was quantified by standard methods: (total cells per high power field: score; 0:0; 1-10:1; 11-50:2; 50-99:3; 100:4). Select cases underwent DNA sequencing analysis using whole exome (WES, &gt; 80X, n = 4) and genome (WGS, &gt; 30X, n = 1) sequencing. Indel analysis was conducted via mutect2 ( &gt; 5% variant allele frequency) and mutational signature was performed using deconstructSigs. Results: The median age was 27 (15-54). Disease status at diagnosis was: 44% localized; 56% metastatic. The median overall survival was 17 yrs (2.9-31). Four patients (pts) received immunotherapy with PD-1 blockade with 1 complete response (CR), 2 durable partial responses (PR) and 1 stable disease (SD). PET was available in 12 cases. PD-1/PD-L1 expression (≥1) was seen in 50% and 17%, respectively. Composite CD3, CD4 and CD8 infiltration were 2, 1, and 1, respectively. Patients with CR/PR to PD-1 blockade (n = 3) had no clear correlation with PD-1, PD-L1 or lymphocyte markers. Exomic characterization (n = 4) demonstrated no clear excess mutation burden compared to Ewing sarcoma (5.7 vs 6.4 mut/MB). Mutational signatures via COSMIC were identified in the mismatch repair (MMR) pathway in 2 of 4 cases (Pt A: Signature (S) 26; pt B: S6 and S15). Pt B also underwent WGS which confirmed a COSMIC signature in the MMR pathway. Indel analysis did not confirm aberrations in standard MMR or polymerase genes. Conclusions: Preliminary findings suggest activity with PD-1 blockade in ASPS; however, this does not appear to correlate with tumour-infiltrating T lymphocytes. Genomic analysis suggests an MMR signature may account for these responses, but standard MMR aberrations were not identified. Further validation is underway.
La gripe aviar A/H5N1 en la Unión Europea –niveles actuales de riesgo para los humanos y respuesta a casos y brotes humanos
Authors: S De Martin, A Nicoll, D Coulombier
Journal: Eurosurveillance (2006)

Esta edicion de Eurosurveillance incluye un informe de Georgia Spala y sus colaboradores describiendo una sospecha de brote de casos humanos de gripe aviar A/H5N1en Grecia [1]. Esto tuvo lugar a principios de la primavera de 2006, cuando en varios paises de la Union Europea (UE) se describieron casos de infecciones por A/H5N1 en aves salvajes. Dichas infecciones se confirmaron en aves en Grecia, pero tras las investigaciones, no fue confirmado ningun caso humano. Sin embargo, las encuestas y controles masivos que se realizaron alrededor de los casos y de las defunciones en el brote de Turquia en diciembre 2005 y enero de 2006 [2] nos recuerdan lo que hubiera podido pasar en Grecia u otros paises de la UE.
New Criteria Needed for Antisynthetase Syndrome—Reply
Authors: Shigeaki Suzuki, Akinori Uruha, Ichizo Nishino
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 12444: Toll-like Receptor 3 is Required for Neonatal Heart Repair and Regeneration Following Myocardial Infarction via Glycolysis Dependent Yap/taz Activation
Authors: Xiaohui Wang, Yuanping Hu, Tuanzhu Ha, He Ma, Li Liu, John Kalbfleisch, Race Kao, David Williams, Chuanfu Li
Journal: Circulation (2015)

Regenerative therapies for repair of the damaged heart could benefit millions of patients annually. The neonatal heart has the capability of repairing/regenerating damaged myocardium. However, this capability is lost when cardiomyocyte metabolism changes from glycolysis to oxidative phosphorylation, within 7 days after birth. Interestingly, Toll-like receptors (TLRs) are required for somatic cell nuclear reprogramming, which is important for tissue regeneration. The Hippo pathway effector YAP promotes cardiac regeneration. We have reported that TLR ligands can induce protection against myocardial ischemic injury. We hypothesized that TLRs are required for cardiac regeneration in neonatal heart via glycolysis dependent YAP/TAZ activation. To evaluate our hypothesis, myocardial infarction (MI) was induced in one day of wild type (WT) and TLR3 deficient (TLR3 -/- ) neonatal mice (n=5/group). Cardiac function was examined by echocardiography 3 weeks after MI. Cardiomyocyte regeneration and proliferation were examined by histone3 phosphorylation (p-histone3) and EdU incorporation into the cardiomyocytes. In WT neonatal MI mice, cardiac function completely recovered, infarct size was smaller, more p-histone3, EdU was incorporated into the cardiomyocytes, and YAP/TAZ activation was significantly increased following MI. In contrast, TLR3 -/- neonatal hearts showed impaired cardiac function, larger infarct size, less p-histone3 and EdU incorporation and inactivation of YAP/TAZ after MI. To examine whether stimulation of TLR3 will promote glycolysis, cardiomyocytes were isolated from one day old WT neonatal mice and treated with Poly I:C, the TLR3 ligand. Poly I:C treatment significantly increases lactate production, NAD + /NADH ratio, extracellular acidification (ECAR) and YAP/TAZ activation. However, inhibition of glycolysis with 2-Deoxyglucose (2DG) prevented Poly I:C-induced neonatal cardiomyocyte proliferation and regeneration as well as YAP/TAZ activation. In vivo treatment of WT neonatal mice with 2DG (n=6/group) abolished cardiac functional recovery 3 weeks after MI. We conclude that TLR3 is required for neonatal heart regeneration and repair after MI. The mechanisms involve glycolysis dependent activation of YAP/TAZ.
Systemic Lipid Peroxydation and Myocardial Superoxide/Peroxynitrite Anions as Predictors of Post-Operative Outcome in Cardiac Surgery
Authors: M Margaritis, C Antoniades, D Tousoulis, M Demosthenous, A S Antonopoulos, C Bakogiannis, D Lymperiadis, C Psarros, B Casadei, C Stefanadis
Journal: Circulation (2011)
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Authors: Lauren C. Harshman, Yu-Hui Chen, Glenn Liu, Michael A. Carducci, David Jarrard, Robert Dreicer, Noah Hahn, Jorge A. Garcia, Maha Hussain, Daniel Shevrin, Mario Eisenberger, Manish Kohli, Elizabeth R. Plimack, Matthew Cooney, Nicholas J. Vogelzang, Joel Picus, Robert Dipaola, Christopher J. Sweeney
Journal: Journal of Clinical Oncology (2017)

Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-sensitive prostate cancer. Methods We performed a landmark survival analysis at 7 months using the E3805 Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) database ( ClinicalTrials.gov identifier: NCT00309985). Inclusion required at least 7 months of follow-up and PSA levels at 7 months from ADT initiation. We used the prognostic classifiers identified in a previously reported trial (Southwest Oncology Group 9346) of PSA ≤ 0.2, > 0.2 to 4, and > 4 ng/mL. Results Seven hundred nineteen of 790 patients were eligible for this subanalysis; 358 were treated with ADT plus docetaxel, and 361 were treated with ADT alone. Median follow-up time was 23.1 months. On multivariable analysis, achieving a 7-month PSA ≤ 0.2 ng/mL was more likely with docetaxel, low-volume disease, prior local therapy, and lower baseline PSAs (all P ≤ .01). Across all patients, median overall survival was significantly longer if 7-month PSA reached ≤ 0.2 ng/mL compared with > 4 ng/mL (median survival, 60.4 v 22.2 months, respectively; P < .001). On multivariable analysis, 7-month PSA ≤ 0.2 and low volume disease were prognostic of longer overall survival (all P < 0.01). The addition of docetaxel increased the likelihood of achieving a PSA ≤ 0.2 ng/mL at 7 months (45.3% v 28.8% of patients on ADT alone). Patients on ADT alone who achieved a 7-month PSA ≤ 0.2 ng/mL had the best survival and were more likely to have low-volume disease (56.7%). Conclusion PSA ≤ 0.2 ng/mL at 7 months is prognostic for longer overall survival with ADT for metastatic hormone-sensitive prostate cancer irrespective of docetaxel administration. Adding docetaxel increased the likelihood of a lower PSA and improved survival.
Assessment of a dyspnea clinic for patients with thoracic malignancies.
Authors: John R. Goffin, Anthony Kerigan, Sharon Ann Russell, Karen Ellis, Dorothy Edwards, Linda Young, Lorraine Martelli, Marissa Slaven
Journal: Journal of Clinical Oncology (2014)

e20667 Background: Dyspnea is a common but undertreated symptom among patients with thoracic malignancies. To meet this need, a multidisciplinary dyspnea clinic was initiated at a tertiary cancer centre. Methods: Patients with a thoracic malignancy and an Edmonton Symptom Assessment Scale (ESAS) dyspnea score of 7 or higher (scale of 0-10) were invited to the clinic. Referrals were also accepted. Patients responded to quality of life questionnaires: ESAS, Cancer Dyspnea Scale (CDS, scores of 12 to 60), EORTC QLQ30, and a satisfaction survey (scales of 0-4). Spirometry, a 6-minute walk test, and chest imaging were performed. All patients received teaching in breathing strategies according to need. Data collection had ethics approval and statistical testing was by Wilcoxon signed rank test. Results of the first 44 patients are reported. Results: From October, 2010, to January, 2012, 44 patients were recruited, 23 with incurable disease. Twenty-five men and 19 women attended the clinic, median age 68.6 (range 48-84), median ESAS for dyspnea of 8 (range 6-10), and median palliative performance scale 80 (range 50-100). Diagnoses included non-small cell lung cancer (31), small cell lung cancer (8), mesothelioma (3), and other (2). At baseline visit, 30 patients used inhalers, 6 oral steroids, 22 narcotics, and 6 home oxygen. Eighteen patients met spirometric criteria for obstructive lung disease. Eight subjects had some degree of pleural effusion but none required drainage. After assessment, 18 patients were prescribed inhalers (9 for the first time), 6 oral corticosteroids, 9 narcotics, and 5 home oxygen. Among 26 patients with at least one follow-up visit, ESAS dyspnea scores improved (median 6.5 vs. 8, p=0.01) as did CDS score (median 29 vs. 32, p=0.03), but not global quality of life. In follow-up, 17 of 21 respondents felt they understood their dyspnea better and 18 would recommend the clinic to another patient. Conclusions: The dyspnea clinic was well-received by patients. An unexpected proportion of dyspneic patients were receiving curative treatment. Obstructive lung disease was a common finding, and both inhalers and palliative interventions were commonly employed. Improvements in ESAS and CDS scores were seen among patients undertaking follow-up.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Authors: Thomas Powles, Ignacio Durán, Michiel S van der Heijden, Yohann Loriot, Nicholas J Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta M Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwenaëlle Gravis, Syed Hussain, Toshimi Takano, Ning Leng, Edward E Kadel, Romain Banchereau, Priti S Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina L Derleth, Marjorie C Green, Alain Ravaud
Journal: The Lancet (2017)
Surveillance sérologique de la rubéole en Europe : le réseau européen ESEN2
Authors: A Nardone, E Miller
Journal: Eurosurveillance (2004)

La surveillance serologique est un outil important pour l'evaluation des programmes de vaccination, en particulier pour les maladies comme la rubeole, ou un programme sub-optimal peut conduire a une augmentation de la morbidite. Une politique de vaccination coordonnee est necessaire en Europe et l'objectif du Reseau europeen d'epidemiologie serologique (European Sero-Epidemiology Network - ESEN2) est de standardiser dans 22 pays la surveillance serologique de huit maladies, dont la rubeole.
Group 2 innate lymphoid cells display ILC3-like functional plasticity in asthmatics and non-human primates
Authors: Cameron H. Flayer, Moyar Qing Ge, Daniel G. Tompkins, Maya Juarez, Lisa Miller, Christopher M. Royer, Brian M. Morrissey, Nicholas J. Kenyon, Angela Haczku
Journal: Journal of Allergy and Clinical Immunology (2018)
Opioid Emergency Declared
Authors: Bridget Kuehn
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diseminación de un clon de SARM (MRSA) con heterorresistencia a la oxacilina en los Países Bajos
Authors: W J B Wannet
Journal: Eurosurveillance (2002)

Desde 2001, en los Paises Bajos se ha observado un incremento en el numero de cepas de SARM con heterorresistencia a la oxacilina. La diseminacion de estas cepas puede pasar desapercibida, pues su resistencia fenotipica heterogenea a las betalactamas afecta los resultados de los analisis de sensibilidad. Por consiguiente, se recomienda realizar pruebas de aglutinacion por latex PBP2a o PCR.